Conjunctive heparin therapy. Limitations of subcutaneous administration.
- 1 November 1992
- journal article
- abstracts
- Published by Wolters Kluwer Health in Circulation
- Vol. 86 (5), 1639-1641
- https://doi.org/10.1161/01.cir.86.5.1639
Abstract
No abstract availableThis publication has 19 references indexed in Scilit:
- Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusionJournal of the American College of Cardiology, 1992
- ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41 299 cases of suspected acute myocardial infarctionThe Lancet, 1992
- Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial.Heart, 1992
- Recombinant hirudin reduces the incidence of thrombotic occlusion in a canine model of coronary vascular injuryCoronary Artery Disease, 1991
- Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarctionThe American Journal of Cardiology, 1990
- In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparinThe Lancet, 1990
- Reduction in Fatal Pulmonary Embolism and Venous Thrombosis by Perioperative Administration of Subcutaneous HeparinNew England Journal of Medicine, 1988
- Fixed minidose warfarin: a new approach to prophylaxis against venous thrombosis after major surgery.BMJ, 1987
- Circadian changes in anticoagulant effect of heparin infused at a constant rate.BMJ, 1985